Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Recurrence 2Diffuse Intrinsic Pontine Glioma 2Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Re-Irradiation × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

NCT01469247 2022-10-20

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

M.D. Anderson Cancer Center

Phase 1/2 Completed
12 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡